Cargando…
Impaired glucose regulation, SARS-CoV-2 infections and adverse COVID-19 outcomes
Impaired glucose regulation (IGR) is common world-wide, and is correlated with Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) the virus that causes Coronavirus disease 2019 (COVID-19). However, no systematic reviews are available on the topic, and little is known about the strength of...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575538/ https://www.ncbi.nlm.nih.gov/pubmed/34763125 http://dx.doi.org/10.1016/j.trsl.2021.11.002 |
_version_ | 1784595693328924672 |
---|---|
author | Roy, Sumith Demmer, Ryan T. |
author_facet | Roy, Sumith Demmer, Ryan T. |
author_sort | Roy, Sumith |
collection | PubMed |
description | Impaired glucose regulation (IGR) is common world-wide, and is correlated with Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) the virus that causes Coronavirus disease 2019 (COVID-19). However, no systematic reviews are available on the topic, and little is known about the strength of the evidence underlying published associations. The current systematic review identified consistent, reproducible associations but several limitations were observed including: (1) a consistent lack of robust confounder adjustment for risk factors collected prior to infection; (2) lack of data on insulin resistance or glycemia measures [Hemoglobin A1c (HbA1c) or glucose]; (3) few studies considering insulin resistance, glucose or HbA1c values in the clinically normal range as a predictor of SARS-CoV-2 risk; (4) few studies assessed the role of IGR as a risk factor for infection among initially uninfected samples; (5) a paucity of population-based data considering SARS-CoV-2 as a risk factor for the onset of IGR. While diabetes status is a clear predictor of poor prognosis following a SARS-CoV-2 infection, causal conclusions are limited. It is uncertain whether interventions targeting dysglycemia to improve SARS-CoV-2 outcomes have potential to be effective, or if risk assessment should include biomarkers of diabetes risk (ie, insulin and glucose or HbA1c) among diabetes-free individuals. Future studies with robust risk factor data collection, among population-based samples with pre-pandemic assessments will be important to inform these questions. |
format | Online Article Text |
id | pubmed-8575538 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85755382021-11-09 Impaired glucose regulation, SARS-CoV-2 infections and adverse COVID-19 outcomes Roy, Sumith Demmer, Ryan T. Transl Res Review Article Impaired glucose regulation (IGR) is common world-wide, and is correlated with Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) the virus that causes Coronavirus disease 2019 (COVID-19). However, no systematic reviews are available on the topic, and little is known about the strength of the evidence underlying published associations. The current systematic review identified consistent, reproducible associations but several limitations were observed including: (1) a consistent lack of robust confounder adjustment for risk factors collected prior to infection; (2) lack of data on insulin resistance or glycemia measures [Hemoglobin A1c (HbA1c) or glucose]; (3) few studies considering insulin resistance, glucose or HbA1c values in the clinically normal range as a predictor of SARS-CoV-2 risk; (4) few studies assessed the role of IGR as a risk factor for infection among initially uninfected samples; (5) a paucity of population-based data considering SARS-CoV-2 as a risk factor for the onset of IGR. While diabetes status is a clear predictor of poor prognosis following a SARS-CoV-2 infection, causal conclusions are limited. It is uncertain whether interventions targeting dysglycemia to improve SARS-CoV-2 outcomes have potential to be effective, or if risk assessment should include biomarkers of diabetes risk (ie, insulin and glucose or HbA1c) among diabetes-free individuals. Future studies with robust risk factor data collection, among population-based samples with pre-pandemic assessments will be important to inform these questions. Elsevier Inc. 2022-03 2021-11-09 /pmc/articles/PMC8575538/ /pubmed/34763125 http://dx.doi.org/10.1016/j.trsl.2021.11.002 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Article Roy, Sumith Demmer, Ryan T. Impaired glucose regulation, SARS-CoV-2 infections and adverse COVID-19 outcomes |
title | Impaired glucose regulation, SARS-CoV-2 infections and adverse COVID-19 outcomes |
title_full | Impaired glucose regulation, SARS-CoV-2 infections and adverse COVID-19 outcomes |
title_fullStr | Impaired glucose regulation, SARS-CoV-2 infections and adverse COVID-19 outcomes |
title_full_unstemmed | Impaired glucose regulation, SARS-CoV-2 infections and adverse COVID-19 outcomes |
title_short | Impaired glucose regulation, SARS-CoV-2 infections and adverse COVID-19 outcomes |
title_sort | impaired glucose regulation, sars-cov-2 infections and adverse covid-19 outcomes |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575538/ https://www.ncbi.nlm.nih.gov/pubmed/34763125 http://dx.doi.org/10.1016/j.trsl.2021.11.002 |
work_keys_str_mv | AT roysumith impairedglucoseregulationsarscov2infectionsandadversecovid19outcomes AT demmerryant impairedglucoseregulationsarscov2infectionsandadversecovid19outcomes |